Studies on the effect of two angiotensin-converting enzyme inhibitors, captopril and cilazapril, on platelet and vascular prostaglandin metabolism in vivo.
We have studied in 12 healthy volunteers the effects of two angiotensin-converting enzyme (ACE) inhibitors, captopril and cilazapril, on vascular and platelet prostaglandin metabolism, in a double-blind, placebo-controlled, randomized cross-over study. Formation of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and thromboxane B2 (TxB2) was measured locally at the site of a microvascular injury. Similar amounts of TxB2 and 6-keto-PGF1 alpha were generated following administration of either ACE inhibitor as compared to placebo. It is concluded that neither captopril nor cilazapril significantly influence vascular and platelet prostaglandin metabolism.
Wagner
B
B
Department of Medicine I, University of Vienna, Austria.
Eichler
H G
HG
Schneider
B
B
Blöchl-Daum
B
B
Brenner
B
B
Gasic
S
S
Lechner
K
K
Kyrle
P A
PA
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000284:Administration, Oral; D000328:Adult; D001760:Bleeding Time; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology*; D017315:Cilazapril / Q000494:pharmacology*; D004311:Double-Blind Method; D011464:Epoprostenol / Q000096:biosynthesis / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D011863:Radioimmunoassay; D011897:Random Allocation; D013929:Thromboxane B2 / Q000097:blood*
D017315:Cilazapril; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D002216:Captopril; D011464:Epoprostenol